Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Berodual®

Study type: Observational

Funder types: Industry

Identifiers

NCT02231437

215.1352

Details and patient eligibility

About

The aim of this post-marketing surveillance is to obtain further information about the tolerability of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

Enrollment: 3,488 patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosis of Chronic obstructive respiratory tract disease
• Patients of either sex, including children over 6 years

Exclusion criteria

• Contraindications listed in the Instructions of Use/Summary of Product Characteristics of Berodual® metered-dose inhaler

Trial design

3,488 participants in 1 patient group

chronic obstructive respiratory tract disease patients

Treatment:

Drug: Berodual®